Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-12-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2087.60. On previous day, the ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Launched in late 2015, sales of Nucala have been mounting and last quarter it generated sales of around £91 million. GSK has also filed Nucala with the FDA as a treatment for COPD. Analyst ...

GSK plc has announced that the US Food and Drug Administration (USFDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster ...

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available ...

UK pharma major GSK today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...

Omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Regeneron, Sanofi) and mepolizumab (Nucala, GSK) have varying effectiveness among patients with asthma and obesity, Mustafa said.

Jacob Bell GSK could soon answer Pfizer in the two pharmaceutical companies’ ongoing market battle to develop better meningitis vaccines. By Feb. 14, the FDA will decide whether to approve a shot ...